6/27/23, 11:42 PM BEAMS (morphine 16 mg) Pathway Feedback Search Clinical Topics Home Studies BEAMS (morphine 16 mg) BEAMS (morphine 16 mg) Disease Disease Chronic obstructive pulmonary Dyspnea in palliative care Trial question What is the effect of ER morphine in patients with COPD? Study design Multi-center Double blinded RCT Population Characteristics of study participants 48.0% female N = 101 52.0% male 101 patients (48 female, 53 male) Inclusion criteria: adult patients with COPD and chronic breathlessness Key exclusion criteria: receipt of opioids; morphine allergy; central hypoventilation syndrome; pregnancy; liver or kidney failure Interventions N=51 morphine (at an ER oral dose of 16 mg/day) N=50 placebo (matching placebo given daily) Primary outcome Reduction in intensity of worst breathlessness at week 1 1.0 1 0.8 0.7 0 5 https://web.pathway.md/studies/recUnIkfyNP85Y49a 1/2 6/27/23, 11:42 PM BEAMS (morphine 16 mg) Pathway 0.5 0.3 No significant difference 0.0 Morphine Placebo No significant difference in reduction in intensity of worst breathlessness at week 1 (1 vs. 0.7; AD 0.3, 95% CI -0.4 to 1) Secondary outcomes Significant increase in reduction in daily step count at week 1 (399 vs. -99; AD 388, 95% CI -277 to -1053) No significant difference in reduction in overall breathlessness distress level at week 1 (1.3 vs. 0.7; AD 0.4, 95% CI -0.4 to 1.2) Safety outcomes No significant differences in nausea, anxiety, dyspnea. Conclusion In adult patients with COPD and chronic breathlessness, morphine was not superior to placebo with respect to reduction in intensity of worst breathlessness at week 1. Reference Magnus Ekstr m, Diana Ferreira, Sungwon Chang et al. Effect of Regular, Low-Dose, Extended- release Morphine on Chronic Breathlessness in Chronic Obstructive Pulmonary Disease: The BEAMS Randomized Clinical Trial. JAMA. 2022 Nov 22;328(20):2022-2032. Open reference URL https://web.pathway.md/studies/recUnIkfyNP85Y49a 2/2